Abstract Library

#1689 The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors

Introduction: The expression of cytokeratins (CK) 7,19 rarely occurs in the low grade neuroendocrine tumors (NET) of lung and pancreas. It is known that part of the low grade typical (TC) and atypical (ATС) carcinoids of lung and pancreas (pNET-G1,G2) can progress quickly and to metastasize. It is important to distinguish NET with a less differentiated cells immunophentype.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Gurevich L, Korsakova N, Voronkova I, Kazanceva I, Ashevskaya V,

Keywords: neuroendocrine tumors, cytokeratin 7, 19 expression, lung, pancreas, prognostic factors,

#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.

Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: De Robertis R

Authors: Ortolani S, De Robertis R, D'Onofrio M, Cingarlini S, Crosara S,

Keywords: perfusion CT, pancreas neuroendocrine tumor, everolimus,

#1198 Role of Combined 68Ga-DOTATOC and 18F-FDG PET-CT in the Diagnostic Workup of Well Differentiated Pancreas Neuroendocrine Tumors (PanNETs): A Surgical Series

Introduction: PanNETs have a broad spectrum of aggressiveness. Somatostatin-receptor based functional imaging, [68Ga]DOTATOC-PET/CT (GP), is recommended in the diagnostic workup of PanNETs; preliminary evidences show that [18F]FDG-PET/CT (FP) can provide prognostic information.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ortolani S, Butturini G, Malpaga A, Cingarlini S, Malfatti V,

Keywords: pancreas neuroendocrine tumor, PET, tumor grade,

#704 Carbohydrate Metabolism Disorders in Patients with Pancreas Neuroendocrine Tumors (PNET) Based on Patients from Department of Endocrinology in 2009-2011

Introduction: Pancreatic Neuroendocrine Tumors (PNET), 80% of which are non-functioning, can be hormonally active.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Andrysiak-Mamos E, Zochowska E, Sowińska-Przepiera E, Syrenicz J, Syrenicz A,

Keywords: neuroendocrine tumors, somatostatin,